Mostrar el registro sencillo del ítem

Artículo

dc.creatorAmpuero Herrojo, Javieres
dc.date.accessioned2022-11-11T14:07:10Z
dc.date.available2022-11-11T14:07:10Z
dc.date.issued2022
dc.identifier.citationAmpuero Herrojo, J. (2022). General overview about the current management of nonalcoholic fatty liver disease. Clinical Drug Investigation, 42, 39-45. https://doi.org/10.1007/s40261-022-01142-w.
dc.identifier.issn1173-2563es
dc.identifier.issn1179-1918es
dc.identifier.urihttps://hdl.handle.net/11441/139327
dc.description.abstractNonalcoholic fatty liver disease includes a wide spectrum of manifestations from simple steatosis to nonalcoholic steatohepa titis, fbrosis, and eventually cirrhosis or even hepatocellular carcinoma. This disorder is also associated with an increased cardiovascular risk, renal involvement, oncologic processes, metabolic disturbances, and an increased risk of all-cause mortality or hepatic mortality. For this reason, nonalcoholic fatty liver disease should be considered a disorder with high morbidity and mortality that must be diagnosed appropriately as soon as possible to establish adequate treatment. Noninva sive methods based on biochemical parameters should be used as a frst step in the evaluation of any patient in whom this disease is suspected. However, serum/blood levels of liver enzymes are not a good indicator of liver damage and noninvasive methods, including biochemical tests and imaging, have suboptimal accuracy or are patented prototypes that show limita tions in clinical practice. There are currently no drugs specifcally approved for the treatment of these liver disorders, thus the most relevant intervention for nonalcoholic fatty liver disease is lifestyle modifcation.es
dc.formatapplication/pdfes
dc.format.extent7 p.es
dc.language.isoenges
dc.publisherADIS INTERNATIONAL LTDes
dc.relation.ispartofClinical Drug Investigation, 42, 39-45.
dc.rightsAtribución-NoComercial 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subjectHepatic and extrahepatic manifestationses
dc.subjectFatty liver diseasees
dc.subjectNon-alcoholic fatty liver disease (NAFLD)es
dc.titleGeneral overview about the current management of nonalcoholic fatty liver diseasees
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Medicinaes
dc.relation.publisherversionhttps://link.springer.com/article/10.1007/s40261-022-01142-wes
dc.identifier.doi10.1007/s40261-022-01142-wes
dc.journaltitleClinical Drug Investigationes
dc.publication.volumen42es
dc.publication.initialPage39es
dc.publication.endPage45es

FicherosTamañoFormatoVerDescripción
General Overview.pdf878.6KbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Atribución-NoComercial 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Atribución-NoComercial 4.0 Internacional